ASX ANNOUNCEMENT August 25, 2011 ___________________________________________________________________________________ Genetic Technologies Executes Settlement and License Agreement with Attomol GmbH
In compliance with ASX Continuing Disclosure Rules, Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to report that it has now executed a Settlement and License Agreement with Attomol GmbH (“Attomol”) of Lipten, Germany. Under the Agreement, Attomol is granted nonexclusive rights to a number of GTG patents relating to its non-coding DNA technology. As with other similar agreements, the precise commercial terms of the Agreement are covered by formal confidentiality provisions and cannot be disclosed. Attomol was not a counterparty to any of the ongoing formal assertion suits filed by GTG in the US. Discussions with other parties are ongoing and progressing. Further details will be released to the Market as appropriate.